Previous 10 | Next 10 |
In 2019, tiny Axsome Therapeutics (NASDAQ: AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech, Novavax (NASDAQ: NVAX) , came out of nowhere to stomp the stock mark...
BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, announ...
Pieris Pharmaceuticals (NASDAQ:PIRS): Q2 GAAP EPS of -$0.25 beats by $0.02. Revenue of $3.29M (-70.8% Y/Y) beats by $1.21M. Cash and cash equivalents totaled $119.1M for the quarter ended June 30, 2021, compared to a cash and cash equivalents balance of $70.4M for the year ended December 31, ...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibro...
Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer Shane Olwill, Ph.D., promoted to Chief Development Officer BOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biothera...
BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today annou...
Jefferies has reiterated its buy rating on shares of Pieris Pharmaceuticals ([[PIRS]] +3.5%) and has raised its price target from $6 to $8.Analyst Roger Song writes that the announcement on June 25 that the company secured a a €14.2M (~$17M) grant for the development of PRS-220 fo...
Fuwei Films (FFHL) +56% on Q1 results.Osmotica Pharmaceuticals (OSMT) +44% on deal to sell business and manufacturing facility.Pieris Pharmaceuticals (PIRS) +21% on development plans for PRS-220 in lung disease.Property Solutions Acquisition (PSAC) +16% on b...
Pieris Pharmaceuticals (PIRS) jumps 17% premarket after announcing the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor, also known as CCN2, for the treatment of idiopathic pulmonary fibrosis ((IPF)).in addition, the Company has bee...
PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary f...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-17 02:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
2024-07-07 05:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...